MedTrace Logo

Exploratory Study of the Expression of the Serotonergic 5-HT4 Receptor in Parkinson's Disease

NCT05916625 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-07

No results posted yet for this study

Summary

The research aim to study in detail the motor, cognitive and affective modifications of Parkinsonian patients (compared to control subjects) at a moderate stage of the disease and to analyze by positron emission tomography (PET) imaging with the specific radioligand \[11C\]SB207145 the expression levels of this 5-HT4 receptor. At the same time, the study will monitor the impact of the 5-HTTLPR polymorphisms of Serotonin Transporter (SERT) and Brain-derived neurotrophic factor (BDNF) Val66Met on the expression of the 5-HT4 receptor in subjects.

Conditions

  • Parkinson Disease

Interventions

OTHER

neuropsychological assessment

a consultation to assess cognitive and psycho-behavioral functions with questionnaires

OTHER

biological sample

10 mL intravenous whole blood collection in EDTA tube

PROCEDURE

medical imagery

Pet scan with the specific radioligand \[11C\]SB207145 and MRI

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Jing XIE · Hospices Civils de Lyon

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2025-09-29
Completion
2025-09-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05916625 on ClinicalTrials.gov